Volume 33, Issue 1, March 2022

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(4):287-9
Assessment of Evidence for COVID-19 and Rheumatic Diseases: Brief Considerations about Immunity and Pathophysiology
Authors Information

Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Z Jadali

  1. Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal Consequences of COVID-19. J Bone Joint Surg Am 2020;102(14):1197-204.
  2. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020;Apr 10:1-8.
  3. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020;20(7):389-91.  
  4. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther 2020;5(1):293.
  5. Butta NV, Fernández-Bello I, López-Longo FJ, Jiménez-Yuste V. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost 2015;41(6):621-8.
  6. Ciaffi J, Meliconi R, Ruscitti P, Berardicurti O, Giacomelli R, Ursini F. Rheumatic manifestations of COVID-19: a systematic review and meta-analysis. BMC Rheumatol 2020;4:65.
  7. Perricone C, Triggianese P, Bartoloni E, Cafaro G, Bonifacio AF, Bursi R, et al. The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun 2020;111:102468.
  8. Robinson PC, Yazdany J. The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic. Nat Rev Rheumatol 2020;16(6):293-4.
  9. Yamamoto K, Takeshita H, Rakugi H. ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. Clin Sci (Lond) 2020;134(22):3047-62.